




SURF25

Section of **URo-Oncology** Forum



Date:

**21 June 2025 (Sat)
22 June 2025 (Sun)**

Venue:

**Zenith Hotel
Putrajaya**



Malaysian
Oncological
Society



MALAYSIAN
UROLOGICAL
ASSOCIATION

Contents

Welcome Messages

- 3 Organising Chairperson (Malaysian Urological Association)
- 4 Organising Chairperson (Malaysian Oncology Society)
- 5 President (Malaysian Urological Association)
- 6 President (Malaysian Oncology Society)

- 7 Organising Committee
- Invited Faculty

Daily Programme

- 8 – DAY 1 (21st June 2025)
- 9 – DAY 2 (22nd June 2025)

Speakers profile

- 10 Local Faculty
- 16 International Faculty
- 20 Information for Speakers and Presenters
- 21 Exhibition Layout
- 22 Exhibitors Profile
- 27 Conference Information
- 28 Acknowledgement

Conference Secretariat

SURF 2025

Conference Secretariat

Malaysian Urological Association

Unit 6-5, Bangunan Perdagangan D6,
801 Jalan Sentul, 51000 Kuala Lumpur, Malaysia.
Email : malaysianurologicalassociation@gmail.com
Website : www.mua.my

Messages

Organising Chairperson
Malaysian Urological Association



**MALAYSIAN
UROLOGICAL
ASSOCIATION**



Dear Delegates, Colleagues, and Distinguished Guests,

On behalf of the organizing committee, I am delighted to extend a warm welcome to all of you at SURF 2025. We are truly excited to have you with us at this pivotal event, where we will collectively explore the latest innovations and advancements in the diagnosis, treatment, and management of Uro-Oncological diseases.

Over the next two days, this forum will provide a dynamic platform for collaboration, knowledge-sharing, and the exchange of groundbreaking ideas. We are honoured to host renowned experts from across the field, whose insights and expertise will inspire progress and innovation in Uro-Oncology. This gathering is not only an opportunity to gain invaluable knowledge but also to connect with peers, build new partnerships, and contribute to the ongoing improvement of patient care.

I would like to take a moment to express my heartfelt gratitude to our co-organizing chairperson, Dr. Flora Chong, Mr Vincent Khor our Scientific Chairman, the committee members, esteemed speakers, and sponsors, whose unwavering support has been instrumental in making this event a reality. A special thanks also goes to the Department of Urology at Universiti Putra Malaysia and Puan Najatuhima Abdul Wahab from MUA, whose contributions have helped ensure the success of this event.

We sincerely hope that your time here will be enriching, inspiring, and leave you with not only new insights but also a renewed enthusiasm to continue driving forward the field of Uro-Oncology.

Once again, welcome to SURF 2025, and we look forward to an engaging and productive forum together.

Warm regards,

Dr Mohd Razaleigh Yusof

Organizing Chairperson, SURF 2025
Malaysian Urological Association

Messages

Organising Chairperson
Malaysian Oncology Society



**Malaysian
Oncological
Society**



Greetings Everyone,

SURF 2025 is here once again. On behalf of the organizing committee, I would like to wish all of you a very warm welcome.

SURF, an event that takes place every two years, will be held this year from 21st to 22nd June, at the Zenith Hotel, Putrajaya.

Our committee has worked hard to put forward this 2-day program, which brings together international and local speakers, all of whom are experts in their discipline. This event is a platform for clinicians to connect, share knowledge and exchange ideas, with a common goal of improving and advancing cancer care, particularly in Uro-Oncology.

Uro-Oncology remains a dynamic and evolving field, hence keeping abreast of the latest advancements and multidisciplinary approaches is key to ensuring optimal patient care and outcomes. We hope this event will give you a meaningful educational experience, as well as a wonderful networking opportunity.

I wish to extend my sincere thanks to everyone involved in making this event possible, particularly our co-organizing chairperson, Dr (Mr) Mohd Razaleigh Yusof, as well as all committee members from both the Urology and Oncology fraternities.

Special thanks also to all our distinguished speakers and chairpersons, all sponsors and exhibitors, as well as our SURF 2025 Secretariat, especially Puan Najatushima Abdul Wahab, for their valuable participation and utmost support.

Warm regards,

Dr Flora Chong Li Tze

Organizing Chairperson, SURF 2025
Malaysian Oncological Society

Messages

President
Malaysian Urological Association



**MALAYSIAN
UROLOGICAL
ASSOCIATION**



Dear friends and colleagues.

Assalamualaikum and salam MADANI to all.

It gives me a great pleasure and honour to welcome all faculties and delegates to the 5th SURF meeting in Putrajaya 2025. SURF is a Uro-Oncology meeting that was first conceptualized as a platform to bring Malaysian Urologist and Oncologist together to discuss relevant updates in the field.

Our upcoming program promises to be more scientifically robust, with a distinguished lineup of both international and local speakers. The Malaysian Urological Association would like to welcome all speakers who have taken time off to join us for this meeting. Your sacrifices is very much appreciated.

This year's meeting is co organized by the Malaysian Urological Association and the Malaysian Oncology Society. Special thanks should be given to Mr. Mohd Razaleigh Yusof and Dr. Flora Chong as co-organizing chairpersons. They are assisted by an excellent team of Malaysian Urologist and Oncologist. Our heartfelt gratitude also go to Miss Najatushima Abdul Wahab, Executive Secretary of the Malaysian Urological Association for her excellent work and commitment.

It has been our vision to host SURF meeting every two years. We hope to see an increase in participation from our neighboring ASEAN countries in the future. It will be an excellent opportunity not only to share experiences in managing Uro Oncology challenges across borders but will further enhance good relationship between Oncologist and Urologist in the region.

We are also fortunate for the encouraging support from our industrial partners, and we look forward to continuing this valuable partnership to foster further advancements. I sincerely hope this meeting will not only be a good academic exercise but will also provide opportunities to gain new friends. For our international guest, I hope you will find time to enjoy Malaysian cuisine and some local sights.

Have a wonderful meeting.

Dr. Noor Ashani Bin Md. Yusoff

President
Malaysian Urological Association

Messages

President
Malaysian Oncology Society



**Malaysian
Oncological
Society**



On behalf of the executive committee of the Malaysian Oncological Society and the organizing committee of the Section of Uro-Oncology Forum (SURF) 2025, it gives me great pleasure to welcome everyone to this year's congress hosted in Putrajaya.

This is a joint congress organized by the Malaysian Oncological Society (MOS) and Malaysian Urological Association (MUA) once every 2 years, to bring together medical professionals involved in the care of patients with genitourinary malignancies to discuss the basics and to venture the advanced. I am certain that the value from the educational line up will truly benefit all attendees.

My heartiest congratulations to the organizing committee of this herculean task, as it is no easy challenge putting together a programme of this calibre. While learning is in motion, do not forget to relax and enjoy what the modern city of Putrajaya has to offer. Do spend your time to renew old ties and forge new ones, across various specialities, so we can do better for our patients. I am truly thankful to our corporate partners; without their support this event will not be possible.

I wish all of you a very fruitful congress.

Dr Muthukkumaran Thiagarajan

President of the Malaysian Oncological Society 2025-2027

ORGANISING COMMITTEE

Organising Chairperson

Mohd Razaleigh Yusof
Flora Chong Li Tze

Scientific Committee Advisor

Omar Ahmed Fahmy Ahemd

Scientific Committee Chairperson

Vncent Khor Wei Sheng

Scientific Committee Members

Suriaraj Karppaya (Urology)
Umadhevan Kanapathy (Urology)
Audi Adawiah Sulaiman Shah (Oncology)
Vance Koi Yung Chean (Oncology)

FACULTY LIST

INTERNATIONAL FACULTY



Australia

Dr Alison Zhang



Hong Kong

Dr Darren Poon Ming-Chun
Assoc. Prof. Dr Peter Chiu Ka Fung



Singapore

Clin. Assoc. Prof. Dr Jeffrey Tuan Kit Loong
Clin. Asst. Prof. Dr Johan Chan
Assoc. Prof. Dr John Yuen Shyn Peng
Assoc. Prof. Dr Kenneth Chen
Dr Lee Chern Siang



Spain

Prof. Dr Enrique Grande



United Kingdom

Prof. Dr Param Mariappan

LOCAL FACULTY



Assoc. Prof. Dr Adlinda Alip
Dr Ang Choon Seong
Dr Daniel Gan
Assoc. Prof. Dr Fam Xeng Inn
Dr Fong Chin Heng
Dr L Sivaneswaran
Dr Malwinder Singh
Assoc. Prof. Dr Marniza Saad
Dr Mohd Najib Aziz
Dr Muthukkumaran Thiagarajan
Dr Nik Muhd Aslan Abdullah
Adj. Prof. Dr Noor Ashani Md Yusoff
Prof. Dr Ong Teng Aik
Dr Ooi Po Lin
Dr Rufus Jesudass
Clin. Prof. Dr Tan Guan Hee
Dr Tang Shir Ley
Dr Vincent Khor
Dr William Ong Lay Keat
Dr Yeong Uen Yea



21st June 2025

8:00 - 8:20 am	Registration	
8:20 - 8:30 am	Welcoming Address by Organizing Committee Chairpersons	Mohd Razaleigh Yusof Flora Chong

PLENARY 1 - Bladder Cancer

Chairpersons: Marniza Saad (MY) and Dato' Khairul Asri Mohd Ghani (MY)

8:30 - 8:50 am	En-Bloc TURBT - Contemporary Evidences and How I Started	William Ong (MY)
8:50 - 9:10 am	Optimizing MIBC Staging with MRI: What More Can It Offer?	Param Mariappan (UK)
9:10 - 9:30 am	Evolving Perioperative Paradigms for Radical Cystectomy in MIBC	Enrique Grande (Spain)
9:30 - 9:40 am	Adjuvant Radiation Following Cystectomy: An Underutilized Treatment?	Muthukkumaran Thiagarajan (MY)
9:40 - 9:50 am	Questions and Answers	
9:50 - 10:10 am	Debate - Radical Cystectomy vs Bladder Preservation Treatment in MIBC	RC - Param Mariappan (UK) BP - Daniel Gan (MY)
10:10 - 10:40 am	Morning Tea Symposium by Astellas Pharma (M) Sdn Bhd From Trial to Reality: Applying EV-301 Evidence in Complex Later-Line Management of Urothelial Carcinoma	Alison Zhang (AUS)
10:40 - 10:55 am	Break	

PLENARY 2 - Upper Tract Urothelial Cancer

Chairpersons: Ong Teng Aik (MY) and Nur Adila Mokhtar (MY)

11:00 - 11:20 am	Neoadjuvant and Adjuvant Therapy for UTUC: Where Are We At Today?	Adlinda Alip (MY)
11:20 - 11:50 am	Emerging Treatments for Metastatic Urothelial Cancer	Enrique Grande (Spain)
11:50 - 12:10 pm	Management of Synchronous High Grade UTUC and NMIBC	Param Mariappan (UK)
12:10 - 12:30 pm	Case Presentation - cN1 - Neoadjuvant or Upfront Surgery?	Ooi Po Lin (MY)
12:30 - 12:40 pm	Questions and Answers	
12:40 - 1:10 pm	Lunch Symposium by Novartis Corporation Sdn Bhd PSMA-Radioligand Therapy, A Game Changing Treatment Modality	Johan Chan (SG)
1:10 - 1:55 pm	Break	

PLENARY 3 - Prostate Cancer

Chairpersons: Kenneth Chen (SG) and Vance Koi (MY)

2:00 - 2:20 pm	Prostate Cancer Screening: Is the Evidence Enough to Change the Standard?	Ong Teng Aik (MY)
2:20 - 2:40 pm	Contemporary and Emerging Roles of PSMA in Prostate Cancer Diagnosis and Treatment	Tan Guan Hee (MY)
2:40 - 3:00 pm	Innovations in Prostate Cancer Radiotherapy: Rectal Spacers and Emerging Technologies	Nik Muhd Aslan (MY)
3:00 - 3:20 pm	Focal Therapy: The Answer for Overtreatment in Prostate Cancer	Peter Chiu (HK)
3:20 - 3:30 pm	Questions and Answers	
3:30 - 3:50 pm	Afternoon Tea Symposium by Johnson & Johnson Sdn Bhd Advancing mCSPC Care: Integrating Real-World Case Studies and Emerging Treatment Paradigm	Malwinder Singh (MY)

PLENARY 4 - Prostate Cancer

Chairpersons: Peter Chiu (HK), Tan Guan Hee (MY), Rufus Jesudass (MY)

3:55 - 4:15 pm	Beyond the Scalpel: HIFU's Role in Focal Therapy for Prostate Cancer	L Sivaneswaran (MY)
4:15 - 4:35 pm	Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer: Where We Stand and What's Next	John Yuen (SG)
4:35 - 4:55 pm	SBRT in Oligometastatic Prostate Cancer: How Do We Handle It ?	Jeffrey Tuan (SG)
4:55 - 5:15 pm	Cracking the Code: Selecting the Right ARSI for the Right mHSPC patient !	Malwinder Singh (MY)
5:15 - 5:25 pm	Questions and Answers	
5:25 - 5:50 pm	Debate: Radical Prostatectomy versus Radiotherapy for Locally Advanced Prostate Cancer (cT3)	RP - Tan Guan Hee (MY) RT - Tang Shir Ley (MY)
5:50 - 6:15 pm	Break	
6:15 - 7:00 pm	Dinner Symposium by Bristol-Myers Squibb (Singapore) Pte Ltd Optimizing First-Line Treatment in RCC & UC: The Evolving Role of Immunotherapy	Marniza Saad (MY) Lee Chern Siang (SG)



22nd June 2025

7:30 - 8:30 am	Fun Run	
8:30 - 8:40 am	Registration	
8:40 - 9:00 am	Breakfast Symposium by AstraZeneca Sdn Bhd Rapid Fire: The ADT Paradigm - Making the Right Choice for Every Prostate Cancer Patient	William Ong (MY) L Sivaneswaran (MY)

PLENARY 5 - Renal Cancer

Chairpersons: Flora Chong (MY) and Arvind Vashdev Jagwani (MY)

9:05 - 9:35 am	Pushing the Limit for Nephron Preservation: Complex Partial Nephrectomy	Fam Xeng Inn (MY)
9:35 - 9:55 am	The Evolving Role of Radiotherapy in RCC	Darren Poon (HK)
9:55 - 10:15 am	Case Presentation - Neoadjuvant Treatment Prior to IVC Thrombectomy	Vincent Khor (MY)
10:15 - 10:20 am	Questions and Answers	
10:20 - 10:40 am	Morning Tea Symposium by Ipsen Pharma Singapore Pte Ltd Kidney Cancer Breakthroughs: Latest Evidence from ASCO GU	Adlinda Alip (MY)
10:40 - 10:50 am	Break	

PLENARY 6 - Renal Cancer

Chairpersons: Hadi Ab Jalil (MY) and Lim Wei Sern (MY)

10:55 - 11:15 am	Advanced RCC Treatment: What's New and Next ?	Ang Choon Seong (MY)
11:15 - 11:35 am	Role of Cyto-reductive Nephrectomy in the Era of IO/TKI	Mohd Najib Aziz (MY)
11:35 - 11:55 am	Case Presentation : non ccRCC	Yeong Uen Yea (MY)
11:55 - 12:05 pm	Questions and Answers	
12:05 - 12:35 pm	Lunch Symposium by MSD/EISAI Navigating RCC Management: Panel Insights on Optimizing Patient Outcomes	Marniza Saad (MY) Darren Poon (HK)

PLENARY 7 - Testis and Penile Cancer

Chairpersons: Aldrin Jasper Placidus (MY) and Chai Chu Ann (MY)

12:40 - 1:00 pm	Robotic-Assisted Retroperitoneal Lymph Nodes Dissection in Testicular Cancer - Malaysian Experience	Noor Ashani Md Yusoff (MY)
1:00 - 1:20 pm	Minimal Invasive Surgical Approach in Inguinal Lymph Node Management: A Single-Center Journey and Experience	Kenneth Chen (SG)
1:20 - 1:40 pm	Radiation Therapy for Localized Penile Cancer	Rufus Jesudass (MY)
1:40 - 2:00 pm	Systemic Therapy in Penile Cancer: Enhancing Patient Outcomes	Fong Chin Heng (MY)
2:00 - 2:10 pm	Questions and Answers	
2:10 - 2:40 pm	End of Conference	

2:40 - 5:00 pm	VIVA Practices (Uro-Oncology) for Urology Trainees	Exam and pre-exam candidates
----------------	-----------------------------------------------------------	------------------------------

Last updated on : 16 June 2025



**Associate Professor
Dr Adlinda Alip**

BMed (UK), MRCP (Edin), FRCR
(Clinical Oncology) (Lond)

Dr. Adlinda graduated from the University of Southampton, UK, and completed her general medical training before earning the MRCP from the Royal College of Physicians, UK. She obtained the FRCR in Clinical Oncology from the Royal College of Radiologists, UK, and was awarded the Certificate of Completion of Training (CCT) in Clinical Oncology by the General Medical Council, UK, in 2011.

In 2012, Dr. Adlinda joined the University of Malaya as a Senior Lecturer and Clinical Oncologist. She serves as principal and sub-investigator on several ongoing and completed clinical trials. Dr. Adlinda regularly presents at local and international conferences. Her main clinical and research interests include lung, breast, and genitourinary cancers, as well as stereotactic radiosurgery and radiotherapy.



Dr Ang Choon Seong
MBChB(Edinburgh), MRCP(UK)

Dr. Ang Choon Seong is a Medical Oncologist at Sarawak General Hospital (SGH). He graduated from the University of Edinburgh in 2010 and obtained his MRCP in 2017. Dr. Ang completed three years of medical oncology training at the National Cancer Institute Singapore before returning to Malaysia in 2024.

He treats a wide range of solid tumours, with a special interest in gastrointestinal (GI) and genitourinary (GU) oncology. Dr. Ang is a member of the SGH First-in-Human clinical trial team and currently serves as the principal investigator for several Phase 2 and 3 industry-sponsored and investigator-initiated oncology trials.

He is also a subcommittee member of the Asian Clinical Trial Network for Cancer Project (ATLAS), where he leads multiple projects focused on real-world data and early-phase interventional trials in rare cancers.



Dr Daniel Gan
MBBS(Malaya), MRCP(UK),
MCO(Malaya)

Dr. Daniel Gan is a Clinical Oncologist at Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (UKM). He earned his MBBS from the University of Malaya in 2013 and became a Member of the Royal College of Physicians (UK) in 2017. He completed his Master of Clinical Oncology at the University of Malaya in 2022 and subsequently obtained the Specialty Certificate in Medical Oncology from the Royal College of Physicians, UK, in 2023.

Dr. Gan is actively involved in multidisciplinary team discussions and clinical trials, with a focus on lung, colorectal, and genitourinary cancers. Alongside his clinical duties, he is deeply committed to medical education and contributes to teaching in the Master of Clinical Oncology program.

He is a member of both the Malaysian Oncological Society (MOS) and the European Society for Medical Oncology (ESMO).



**DAssoc. Prof.
Dr Fam Xeng Inn**
MD(UKM), DrGenSurg(UKM),
FRCS(Urol)(Glasgow),
AM Fellowship in Laparoscopic &
Robotic Surgery (Beijing China)

Dr Fam Xeng Inn is a highly respected Consultant Urologist with extensive expertise in laparoscopic, robotic, endourological, and uro-oncological surgeries. He previously served as an Associate Professor of Urology at the Faculty of Medicine, Universiti Kebangsaan Malaysia, and continues to contribute actively to medical education and surgical training.

Dr Fam plays a pivotal role in the Asian Urological Surgery Training and Education Group (AUSTEG), where he is involved in advancing surgical training across the region. He is internationally recognised for his skill in complex robotic urological cancer surgeries, particularly in kidney-sparing procedures for complex renal tumors and continence-preserving techniques in prostate cancer surgery. Renowned for his patient-centred approach, Dr Fam also serves as a robotic surgeon and proctor at Hospital Picaso, Malaysia, where he mentors fellow surgeons and supports the development of advanced urological care both locally and globally.



Dr Fong Chin Heng
MD(USM), MCO(Malaya)

Dr. Fong Chin Heng earned his MD degree from Universiti Sains Malaysia (USM) in 2003 and completed his formal training in the Master's program in Clinical Oncology at Universiti Malaya in 2012. Following his specialization, he served for three years at Hospital Sultan Ismail in Johor Bahru before returning to Penang General Hospital in 2015.

From 2018 to 2020, Dr. Fong completed a clinical fellowship at the Princess Margaret Cancer Centre in Toronto, Canada, where he focused on advanced treatments for central nervous system tumors and brain metastases, including Gamma Knife radiosurgery and volumetric modulated arc therapy. He also specialized in genitourinary cancers, with particular emphasis on MRI-guided high-dose-rate brachytherapy for prostate cancer and stereotactic ablative radiotherapy.

Currently, Dr. Fong is a Consultant Clinical Oncologist at both Penang General Hospital and Gleneagles Hospital Penang. He actively contributes to the training of future clinical oncologists through his involvement in the Master of Clinical Oncology program, the National Parallel Pathway program, and the "Train the Trainer" course under the Malaysian national curriculum.



Dr L. Sivanewaran
MBBS (Manipal), MRCS (Ireland),
M. Surg (UM), FRCS Urol (Glasgow),
Fellow in Urology (Melbourne),
M'sian Urology Board Cert, AM (Mal),
FRCS (Ireland)

Dr. L. Sivanewaran is the consultant urologist and head of urology from Hospital Raja Permaisuri Bainun, Ipoh, Perak Malaysia.

Dr. L. Sivanewaran is the Consultant Urologist and Head of the Urology Unit at Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia.

He graduated from Melaka Manipal Medical University in 2005 and completed his Master's in General Surgery at the University of Malaya in 2014. After serving as a general surgeon in Taiping, he joined the national urology training program two years later.

Dr. Siva completed his specialist training under the Malaysian Board of Urology and was awarded a Fellowship by the Royal College of Physicians and Surgeons of Glasgow in 2019. In 2021, he pursued a clinical urology fellowship at The Alfred Hospital in Melbourne, Australia.

Returning to Malaysia in 2022, Dr. Siva became Perak state's first resident urologist, where he established the Urology Unit in Ipoh, which now also serves as a training center. He has authored numerous publications and received multiple international accolades for his research presentations. In 2023, he was awarded the Fellowship ad eundem and admitted as a Fellow of the Royal College of Surgeons in Ireland, in recognition of a decade of academic contributions to the college.

Dr. Siva is a pioneer of prostate cancer focal therapy in Malaysia, utilizing high-intensity focused ultrasound (HIFU), and currently holds the largest case series in Southeast Asia. He is actively involved in expanding focal therapy services across the region as part of the Asian Focal Therapy Society



Dr Malwinder Singh
MBBS(MAHE), MCO(Malaya)

Dr Malwinder Singh earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Melaka Manipal Medical College in 2006 and went on to complete a Master of Clinical Oncology (MCO) at the University of Malaya in 2015.

He advanced his clinical expertise through specialized training in stereotactic radiotherapy (SBRT/SRS/SRT) at the renowned Tata Memorial Hospital in Mumbai, and further advanced his skills in Gamma Knife Radiosurgery at Na Homolce Hospital in Prague, Czech Republic.

Dr Malwinder's clinical practice focuses on advanced radiotherapy techniques, including Gamma Knife Radiosurgery for brain tumors and SBRT for prostate and lung cancers. He has a strong interest in the management of breast, colon, lung, prostate, and brain cancers, and is committed to delivering innovative, patient-centered cancer care.

Throughout his career with Malaysia's Ministry of Health, he has made significant contributions as an oncologist at both Hospital Sultan Ismail and Hospital Kuala Lumpur. Driven by a passion for clinical excellence and research, Dr Malwinder continues to play an integral role in advancing cancer care in Malaysia.



**Associate Professor
Dr Marniza Saad**
MBBCh (Cardiff), FRCR (Lond)

Associate Professor Dr. Marniza Saad has been a Consultant Clinical Oncologist at the Department of Clinical Oncology, University Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia, since 2006. She also holds the position of Associate Professor at the Faculty of Medicine, University Malaya (UM), Kuala Lumpur.

She obtained her medical degree from the University of Wales College of Medicine, Cardiff, United Kingdom, in 1997. She completed her general medical training within the South Wales Medical Rotation in 2000. In 2001, she joined UM as a trainee lecturer in Oncology. She pursued formal training as a Clinical Oncologist at Velindre Cancer Centre in Cardiff, UK, from 2002 to 2006 and was awarded the Fellowship of the Royal College of Radiologists (Clinical Oncology) in 2006.

Dr. Marniza has served as a supervisor and internal examiner for the Master of Clinical Oncology programme at UM since May 2006. As part of the department's Education Committee, she has a deep passion for education and the training of future oncologists in Malaysia. She was Head of the Department of Clinical Oncology at UMMC from 2013 to 2015. During her tenure, she oversaw the development of Stereotactic Radiosurgery/Radiotherapy (SRS/SRT) and Intensity-Modulated Radiotherapy (IMRT), working closely with expert teams to successfully initiate these services at UMMC in May and September 2015, respectively.

She currently serves on the UMMC Intra-Operative Radiotherapy Working Group, aiming to introduce the service at UMMC in the near future. She has been an Executive Committee member of the Malaysian Oncological Society since 2013 and is a member of the College of Radiology, Academy of Medicine Malaysia, as well as the European Society for Medical Oncology.

Her areas of special interest include genitourinary cancer, sarcoma, breast, and gastrointestinal cancers. She is the principal investigator for several international clinical trials, mainly in urological cancers, and regularly speaks on these topics at both local and international conferences.



Dr Mohd Najib Aziz
MBChB(Auck), FRCS(Urol)(Glasgow)

Dr. Mohd Najib is a Consultant Urologist at Hospital Selayang. He earned his Bachelor of Medicine and Bachelor of Surgery (MBChB) from the University of Auckland, New Zealand, in 2011 and was awarded the Fellowship of the Royal College of Surgeons (FRCS) in Urology from Glasgow in 2022.

He further refined his skills by completing a clinical fellowship in Melbourne, Australia, from 2024 to 2025, where he focused on the management of complex oncological urological cases and procedures. Dr. Najib has a particular interest in uro-oncology and advanced urological surgery.

He is also actively involved in mentoring and supervising major urological procedures, reflecting his strong commitment to surgical excellence, education, and the continuous advancement of urological care.



**Dr Muthukkumaran
Thiagarajan**
BScMS(UPM), MD(UPM), MCO(Malaya)

Dr. Muthukkumaran obtained his Master's in Clinical Oncology from the University of Malaya in 2013. He previously served at Sabah Women and Children Hospital and is currently based at the Department of Radiotherapy and Oncology, Hospital Kuala Lumpur.

His clinical interests include pulmonary oncology, genitourinary oncology, neuro-oncology—with a focus on stereotactic cranial radiosurgery—and pediatric radiation therapy. He is actively involved in both industry-sponsored and investigator-initiated clinical research.

Dr. Muthukkumaran currently serves as the President of the Malaysian Oncological Society (MOS). He also represents Malaysia on the Federation of Asian Organizations for Radiation Oncology (FARO) and the International Atomic Energy Agency (IAEA), contributing to regional and international collaborations in cancer care.



Dr Nik Muhd Aslan Abdullah

BSc (UNSW), MBBS (UNSW),
MCO (UM)

Dr Nik Muhd Aslan Abdullah is a highly experienced Medical Oncologist based in Kuala Lumpur, Malaysia, with over 20 years of expertise in the field. He specializes in systemic therapies such as chemotherapy, targeted therapy, and immunotherapy, as well as various radiotherapy techniques including IMRT, VMAT, SRS, SRT, SBRT, and image-guided brachytherapy for gynecological cancers.

He earned his MBBS from the University of New South Wales, Australia, in 1999, and subsequently completed his Master of Clinical Oncology (MCO) at the University of Malaya in 2008.

Dr. Abdullah is an esteemed member of several prestigious professional bodies, including the European Society for Radiotherapy and Oncology (ESTRO), the European Society for Medical Oncology (ESMO), and the Malaysian Oncological Society (MOS).

Fluent in both English and Bahasa Malaysia, Dr. Nik has a particular interest in systemic therapy for adult cancers and advanced radiotherapy approaches, with a strong commitment to delivering patient-centered cancer care.



**Adjunct Professor
Dr Noor Ashani Md Yusoff**

MBBS(Malaya), MSurg(UKM),
FRCS(Urol)(Glasgow),
Fellowship of Robotic Surgery
(Yonsei University, Korea)

Dr Noor Ashani Md. Yusoff is the Senior Consultant Urologist and Head of the Urology Department at Hospital Kuala Lumpur, Malaysia. He also serves as the Head of the Urology Specialty for the Ministry of Health Malaysia and holds the position of President of the Malaysian Urological Association (MUA). Since 2000, he has been appointed as an Adjunct Professor at Hospital Sultan Azlan Shah, Universiti Putra Malaysia (UPM).

Dr Noor Ashani obtained his Master of Surgery (General) from Universiti Kebangsaan Malaysia (UKM) in 2002 and subsequently pursued subspecialty training in urology under the Malaysian Board of Urology, in collaboration with the Ministry of Health and the Malaysian Urological Association. He completed his urology training in 2007 and was awarded the Fellowship of the Royal College of Surgeons in Urology [FRCS (Urology), Glasgow] in 2014.

His primary clinical interest lies in minimally invasive surgery, particularly robotic-assisted laparoscopic surgery. He began his robotic surgery training in 2004 under the mentorship of Dato' Dr Sahabudin Raja Mohamed, the pioneer of robotic surgery in Malaysia. He further advanced his training at Yonsei Severance Hospital in Seoul, Korea, in 2010 under Dr. Khoo Hon Rha, a leading figure in robotic surgery in Korea.

Dr Noor Ashani has performed over 400 robotic-assisted laparoscopic surgeries, ranging from robotic-assisted radical prostatectomy to retroperitoneal lymph node dissection (RAL RPLND). He is recognized as the pioneer of RAL RPLND in Malaysia and holds the largest case series in Southeast Asia. In addition to his clinical work, he has proctored more than 80 robotic-assisted surgeries across Malaysia and is a frequent speaker at both national and international conferences on robotic surgery.



Professor Dr Ong Teng Aik

MBBS(UM), FRCS(Surg)(Ire),
MSurg(UM), FEBU(Uro),
FRCS(Urol)(UK), AM

Professor Dr Ong was born and educated in Kuala Lumpur. He graduated with an MBBS from the University of Malaya in 1995 and served for 15 years in various hospitals across Kuala Lumpur (HKL, UHKL), Sabah, and Sarawak before joining University Malaya Medical Centre (UMMC) in 2010.

He obtained the Fellowship of the Royal College of Surgeons in Ireland in 2000 and completed his Master of Surgery in 2002. Following this, he served as a Senior Lecturer and later as an Associate Professor at Universiti Malaysia Sarawak (UNIMAS), where he received the Excellence in Service Award in 2009.

Dr. Ong received most of his urology training at Sarawak General Hospital under the guidance of senior urologists Dr. Teh Guan Chou and Dr. Clarence Lei. In the same year, he was awarded the British Journal of Urology International (BJUI) Scholarship to further his training in the United Kingdom. He also co-authored a paper on retroperitoneal lymph node dissection with Dr. Timothy Christmas, a renowned surgeon from Charing Cross Hospital, London. He is currently the Professor in Urology and Deputy Dean (Value Creation & Enterprise) at Universiti Malaya.

His main research interest is in uro-oncology.



Dr Ooi Po Lin
MBBS(Malaya), MCO(Malaya)

Dr. Ooi Po Lin graduated with an MBBS from the University of Malaya in 2015 and completed her Master of Clinical Oncology in 2024. She currently manages a wide spectrum of oncology cases, with clinical interests spanning upper and lower gastrointestinal, breast, and urological malignancies — though urological cancers remain her true passion.

Outside the oncology sphere, she's usually found conjugating verbs in new languages or mastering control and precision in Pilates — because balance isn't just for treatment plans.



Dr Rufus Jesudass
MD(UGM), MCO(Malaya)

Dr. Rufus Jesudass is a passionate oncologist and dedicated patient advocate with special interests in central nervous system (CNS), genitourinary, lung, sarcoma, and neuroendocrine tumours. His expertise lies in advanced radiation therapy techniques, including stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and Gamma Knife procedures.

He is also an emerging clinical researcher and investigator, actively involved in trials related to genitourinary and lung cancers.

Dr. Rufus currently serves as a consultant oncologist at Hospital Kuala Lumpur.



**Clin. Professor
Dr Tan Guan Hee**
MBBS(IMU), MRCS(Edinburgh),
MS(UKM), FRCS(Urol) (Glasgow),
Malaysian Board of Urology Certified
Urologist, Fellowship in Urology
(Melbourne), SUO Fellowship in
Uro-Oncology (Toronto)

Dr. Tan Guan Hee is a Consultant Urologist and Head of the Urology Sub-division at Sunway Medical Centre, Malaysia. He also serves as a Clinical Professor at Sunway University.

Dr. Tan completed his sub-specialty training under the Society of Urologic Oncology Fellowship at the University of Toronto, Canada. He is well-trained in minimally invasive surgery and regularly performs robot-assisted procedures, with a focus on prostate and kidney cancers.

An advocate for surgical innovation, Dr. Tan is an early adopter of novel technologies such as fusion transperineal prostate biopsy and PSMA-based theranostics. His research interests lie in smarter screening methods and early diagnosis of prostate cancer



Dr Tang Shir Ley
MBBS(AIMST), MCO(Malaya)

Dr Tang graduated from AIMST University and completed a Master in Clinical Oncology in 2022. Previously based at Hospital Kuala Lumpur, Dr. Tang is currently serving at Hospital Raja Permaisuri Bainun, Ipoh.

Actively involved in multidisciplinary team meetings, tumour boards, and clinical trials, Dr Tang has a special interest in uro-oncology.



Dr Vincent Khor Wei Sheng

MBBS(Manipal), MRCS(Ireland),
ChM(Urol)(Edinburgh),
FRCS(Urol)(Glasgow)

Dr Vincent Khor is a young urologist with a sub-specialty interest in uro-oncology and is currently undergoing training to become an academic urologist. He graduated with an MBBS from Manipal University, India, in 2013, and began his medical career as a house and medical officer in both Malaysia and Singapore.

In 2015, he passed the Intercollegiate MRCS examination from the Royal College of Surgeons in Ireland, furthering his surgical foundation and solidifying his passion for urology. He later obtained a Master of Surgery (ChM) in Urology from the University of Edinburgh in 2019. In November 2024, he completed his urology specialty training under the Malaysian Board of Urology and was awarded the Fellowship of the Royal College of Surgeons (FRCS) in Urology from Glasgow, UK.

Dr Vincent is also a proud alumnus of Harvard Medical School, having completed the Global Clinical Scholars Research Training (GCSRT) program in 2023. In recognition of his contributions to the community and profession, he was honoured with the Ten Outstanding Penang Youth Award in 2024. He also made history as the first Malaysian to receive a scholarship for a short clinical visit from the European Association of Urology.

His research interests include prostate cancer diagnostics, robotic surgery, and focal therapy. Passionate about integrating technology into clinical practice, he developed an app to track ureteral stents in his institution. He has also played a pivotal role in establishing the MRI-ultrasound fusion prostate biopsy and prostate cancer focal therapy services at Universiti Putra Malaysia Teaching Hospital.



Dr William Ong Lay Keat

MBBS(Manipal), MRCS(Ireland),
FRCS(Urol)(Glasgow)

Dr. William Ong is a Consultant Urologist and Head of the Urology Unit at Hospital Sultanah Bahiyah, Malaysia. He earned his MBBS from Manipal University and holds esteemed postgraduate qualifications, including Membership of the Royal College of Surgeons of Ireland (MRCS) and Fellowship of the Royal College of Physicians and Surgeons of Glasgow in Urology (FRCS). He further enhanced his clinical training with a one-year urology fellowship at Queen Elizabeth Hospital, Adelaide, Australia.

Dr. Ong is an active leader in the field, having served as the Organising Chairperson of the 33rd Malaysian Urological Conference (2024) and currently as an Executive Committee member of the Malaysian Urological Association (MUA). His international affiliations include the European Association of Urology (EAU), International Alliance of Urolithiasis (IAU), Société Internationale d'Urologie (SIU), American Urological Association (AUA), and the Global Interstitial Cystitis Bladder Pain Syndrome Society (GIBS).

A dedicated academician, Dr. Ong mentors urology trainees and medical students, frequently speaks at national and international conferences, and contributes to peer-reviewed journals through original research and editorial work. His commitment to clinical excellence has earned him multiple accolades, including an Excellence in Service Award from his alma mater.



Dr Yeong Uen Yea

MBBS(Malaya)

Dr. Yeong obtained her Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Malaya in 2015. She served as a medical officer in Sabah for three years before pursuing her Master of Clinical Oncology at the University of Malaya.



Australia



Dr Alison Zhang
MBBS, FRACP, MMed, PhD

Dr Alison Zhang is a Consultant Genitourinary Medical Oncologist and the Bladder Cancer Lead at Macquarie University Hospital and the Chris O'Brien Lifehouse in Sydney, Australia. With a strong focus on clinical research, she serves as the principal investigator for over 30 industry-sponsored and academic Phase I-IV clinical trials, and as sub-investigator in more than 100 trials. Her research contributions have been published in leading peer-reviewed journals including The New England Journal of Medicine, The Lancet, Lancet Oncology, and The Journal of Clinical Oncology. In addition to her clinical and research roles, Dr Zhang is a Senior Clinical Oncology Research Fellow at NHMRC Clinical Trials Centre, University of Sydney, where she plays an active role in the international coordination and management of genitourinary cancer trials.



Hong Kong



Dr Darren Ming-Chun Poon
MBChB, FRCR, FHKCR, FHKAM
(Radiology)

Dr. Darren Ming-Chun Poon is an Honorary Clinical Associate Professor at The Chinese University of Hong Kong and an Honorary Consultant in Clinical Oncology at both the Hong Kong Sanatorium & Hospital and the Prince of Wales Hospital.

Dr. Poon's clinical expertise spans multiple cancer types, including genitourinary (GU) cancers, neuro-oncology, hepato-pancreatic cancers, and head and neck cancers. His research interests focus on novel therapies for GU cancers, as well as image-guided radiotherapy and stereotactic body radiotherapy (SBRT) for prostate, central nervous system, pancreatic, and liver tumors.

A pioneer in prostate SBRT in Hong Kong, Dr. Poon completed the region's first-in-Asia randomized clinical trial on prostate SBRT. He has authored over 50 original publications, reviews, and abstracts in peer-reviewed journals and is a co-author of the 10th edition of Fast Facts: Prostate Cancer.

He has served as an expert panelist for the Advanced Prostate Cancer Consensus Conference (APCCC) since 2019 and the Asia Pacific APCCC (APAC-APCCC) since 2020. Dr. Poon is also a regular invited speaker at local, regional, and international oncology conferences. He is actively involved in multiple clinical trials investigating innovative therapies for urothelial, bladder, renal, and prostate cancers.

Beyond his clinical and academic roles, Dr. Poon has held leadership positions in various professional societies. He has served as Vice-President of the Hong Kong Society of Uro-Oncology, the Hong Kong Nasopharyngeal Carcinoma Study Group, and the Hong Kong SBRT Study Group. He is also a Council Member of the Hong Kong Prostate Foundation and Vice-Chairman of the Hand in Hand Cancer Foundation.



**Associate Professor
Dr Peter KF Chiu**
MBChB, PhD (EUR), FRCSEd (Urol)

Dr. Peter Chiu graduated from the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) and obtained his Fellowship in Urology from the Royal College of Surgeons of Edinburgh. He pursued postgraduate training in prostate cancer research and andrology at the Erasmus Medical Centre in Rotterdam, The Netherlands, where he also earned a PhD in prostate cancer diagnosis.

Dr. Peter Chiu is currently an Associate Professor in the Division of Urology and Assistant Dean (Translation and Entrepreneurship) at CUHK.

His clinical and research interests are centred on prostate cancer, covering the full spectrum from screening and diagnosis—using novel biomarkers such as the Prostate Health Index and urine spermine—to MRI-guided targeted biopsy and focal therapy. He currently offers focal therapy options including high-intensity focused ultrasound (HIFU), cryotherapy, and targeted microwave ablation (TMA) for localized early prostate cancer.



Singapore



Dr Lee Chern Siang
MBBS(UK), MRCP(UK)

Dr. Lee is a Specialist in Medical Oncology. He received his medical degree at Barts and The London School of Medicine in London, with an intercalated first-class degree in Molecular Medicine in 2005. He completed his internship and general (internal) medicine training in London and Southampton. He then completed specialist Medical Oncology training at University Hospital Southampton NHS Foundation Trust and Portsmouth Hospital University NHS Trust, UK, in 2017. He was appointed a National Institute for Health Research Academic Clinical Fellow during his specialist training and had the opportunity to undertake translational research as a Cancer Research UK Clinical Research Fellow.

Dr. Lee is experienced in the management and treatment of a wide spectrum of cancer patients, having worked across academic research centres and district general hospitals in the UK. He is familiar with current guidelines for evidence-based practice, as well as managing complex cancer patients, including those participating in 'first-in-man' and late-phase clinical studies. He has participated in several large international clinical trials across different cancer types and was the site Principal Investigator in some of these studies.

Dr. Lee's clinical interests include breast cancer, oesophageal and gastric cancer, colorectal cancer, pancreatic cancer (including neuroendocrine cancer), bile duct and gallbladder cancer, liver cancer, immunotherapy, molecular medicine, clinical trials, and patient advocacy, with a special interest in geriatric oncology (cancers in the elderly).



**Clin. Assoc. Prof.
Dr Jeffrey Tuan Kit Loong**
MBBS(NUS), FAMS, FRCR,
MSc (London)

Dr. Jeffrey Tuan Kit Loong is a Senior Consultant at the National Cancer Centre Singapore (NCCS) Radiation Oncology Division and Head of the Gastrointestinal, Hepato-Pancreato-Biliary, and Urology Department. He specializes in advanced radiation therapies for urological and gynaecological cancers, including IMRT, SBRT, and brachytherapy.

As Research Director, Dr. Tuan's work focuses on prostate cancer, tumour tracking, and biomarkers. He holds an MBBS from the National University of Singapore, an MSc from the University of London, and is a Fellow of both the Royal College of Radiologists (UK) and the Academy of Medicine, Singapore (AMS).

Dr. Tuan is also a Clinical Associate Professor at Duke-NUS Medical School and a Clinical Teacher at NTU Lee Kong Chian School of Medicine. He has published over 100 peer-reviewed articles, with more than 1,100 citations.



**Clin. Asst. Prof.
Dr Johan Chan**
BMSc(Hons), MBBS(Hons), FRACP

Dr Johan Chan is a Consultant Medical Oncologist at the National Cancer Centre Singapore and a Clinical Assistant Professor at Duke-NUS Medical School. He received his medical degree with honours in Australia and is a Fellow of the Royal Australasian College of Physicians (FRACP) in Medical Oncology.

Dr Chan's clinical and research interests lie at the intersection of genitourinary, thoracic, and geriatric oncology, with a particular focus on optimizing cancer care in older adults. He is actively involved in translational research and clinical trials, contributing to the evolving landscape of precision oncology and age-adapted cancer management.

With a strong commitment to patient-centered care, Dr Chan combines clinical excellence with a passion for improving outcomes through evidence-based, compassionate practice. He is also a regular speaker in public forums and professional conferences, advocating for early detection, healthy lifestyles, and multidisciplinary collaboration in cancer care.



Singapore



**Associate Professor
Dr John Yuen Shyi Peng**
MBBS(Melb), MMed(Surg)(S'pore),
MRCS(Edin), FAMS(Urology),
DPhil(Oxon)

Associate Professor John SP Yuen studied medicine at the University of Melbourne under an Australian Government scholarship, earning his Bachelor of Medicine and Bachelor of Surgery (MBBS) in 1996. He is currently the Head and Senior Consultant in the Department of Urology at Singapore General Hospital (SGH).

He completed advanced urology training in Singapore, where he earned his Membership of the Royal College of Surgeons of Edinburgh (MRCSEd) in 2000 and a Master of Medicine (Surgery) from the National University of Singapore (NUS). In 2004, he was accepted as a Fellow of the Singapore Academy of Medicine and as a Member of the Urologist Chapter of the Singapore College of Surgeons.

A/Prof Yuen is a Senior Consultant Urological Surgeon specializing in robotic and laparoscopic surgery for urological cancers in Singapore General Hospital, including prostate, kidney, bladder, testicular, and penile cancers. He received robotic and laparoscopic surgical training at the University of Strasbourg, France, and the Roswell Park Cancer Institute in New York, USA, where he was awarded a diploma in laparoscopic surgery.

His subspecialty is in uro-oncology, and he led the service in the Urology Department at SGH from 2013 to 2016. In addition to cancer treatment, he also manages general urological conditions such as benign prostatic hyperplasia (BPH), urinary stone disease, and urinary tract infections.



**Associate Professor
Dr Kenneth Chen**
MBBS, MCI, DFD, MRCS(Edin),
FAMS(Urology), FRCS(Urol)(Glasgow)

Dr. Kenneth Chen is a Senior Consultant Uro-Oncologist at Singapore General Hospital. He earned his medical degree (MBBS) from the National University of Singapore in 2007 and completed a six-year residency in Urology with SingHealth. He passed his specialist board exams with distinction, receiving the Academy of Medicine, College of Surgeons GOLD Medal for the best-performing advanced surgical trainee in Urology. Dr. Chen holds membership and fellowship in the Royal College of Surgeons of Edinburgh and Glasgow, as well as a Master's degree in Clinical Investigation.

Dr. Chen specializes in robotic and minimally invasive surgery for genitourinary oncology, having completed an oncology fellowship at the Sir Peter MacCallum Cancer Centre in Melbourne, Australia. His academic and research interests include prostate cancer diagnostics, advanced prostate cancer management, and novel device development. He has received a National Medical Research Council (NMRC) grant for his work on a drug-eluting stent to treat ureteric diseases.

In addition to his clinical and research work, Dr. Chen is a Clinical Associate Professor at Duke-NUS Graduate Medical School and a Senior Clinical Lecturer at both the National University of Singapore Yong Loo Lin School of Medicine and the Lee Kong Chian School of Medicine. He is actively involved in medical education and training, serving as a faculty member for the SingHealth Postgraduate Year 1 Physician Faculty Program and as core faculty for the SingHealth Urology Residency Program.



Spain



**Professor
Dr Enrique Grande**
MD, PhD, MSc

Dr Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research Lead at MD Anderson Cancer Center Madrid. His clinical and research focus is on genitourinary and endocrine tumors, and he plays an active role in the development of the Translational Research and Early Drug Development Unit.

Dr Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism. He also holds a Master's degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO).

He is the author of more than 300 peer-reviewed publications and is the founder of the Spanish Group for Research on Orphan and Uncommon Tumours (GETHI). Dr Grande serves as an editor for several international journals and has been actively involved in numerous landmark clinical trials in bladder cancer. His work has contributed to the approval of several novel therapies currently in use.

He co-chairs the steering committees for key international trials including IMvigor130, DISCUS, VOLGA, and DV001.



United Kingdom



**Professor
Dr Param Mariappan**
MBBS(Hons), FRCS(Urol),
PhD, FEBU, CBU(Mal)

Professor Param Mariappan has been a Consultant Urological Surgeon in Edinburgh for the past 20 years, with a clinical practice almost exclusively focused on bladder cancer.

With over 950 cystectomies and 6,000 TURBTs performed, he is one of the UK's most experienced bladder cancer surgeons. He leads the bladder cancer surgical service in Edinburgh, emphasizing effectiveness and efficiency in patient-centred care.

Professor Mariappan plays a key role in the development and ongoing implementation of the Scottish Quality Performance Indicator (QPI) programme for bladder cancer and is the architect of the Scot BC Quality OPS project.

He has published extensively (h-index 34), contributing to several seminal works in the field.

He serves on the European Association of Urology (EAU) guideline panels for non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and upper tract urothelial carcinoma (UTUC), and is currently Vice Chair of the MIBC panel. He is also a core committee member of the International Bladder Cancer Group (IBCG).

Outside of his professional life, Professor Mariappan is a keen golfer, playing off a 6 handicap.



Registration Counter	Foyer of the Grand Ballroom, Level 1, The Zenith Hotel Putrajaya
Operating Hour	21 st June 2025 0730 – 1700 22 nd June 2025 0730 – 1200
Welcome and Introduction	Date : 21 st June 2025 Time : 0830 – 0845 Venue : Grand Ballroom, Level 1, The Zenith Putrajaya
Powerpoint Presentation	Presentation using personal laptop is not encouraged. Please save your presentation USB Drive and load it on the congress laptop by the AV assistant for identification.

Guidelines for Speakers and Chairpersons

Speakers' Preview Room

The Speakers' Preview Room is allocated at Zenith IV

Guidelines for Speakers – Scientific Session

Please submit your presentation at least 3 hours in an USB Drive for uploading on the Congress laptop by the AV Assistant prior to your presentation.


Audio-visual testing facilities are available for your testing and viewing. The staff on duty will assist you in testing and installing your presentation materials. Please note that only **PowerPoint by Microsoft Office** will be available.

Please be present at your session room at least **10 minutes** prior to the start of the session.

Guidelines for Chairpersons

Chairpersons are appointed to moderate and conduct each scientific presentation in an orderly and systematic manner as per the schedule.

All questions and answers should be done at the end of each plenary session when all panels are called to be seated on stage.



1	Novartis Corporation Sdn Bhd
2	Astellas Pharma (M) Sdn Bhd
3	Bristol-Myers Squibb (Singapore) Pte Ltd
4	Merck Sdn Bhd
5	Ipsen Pharma Singpoare Pte Ltd
6	Merck Sharpe & Dohme (M) Sdn Bhd
7	AstraZeneca Sdn Bhd
8	Novugen Sdn Bhd
9	SYS Healthcare Sdn Bhd
10	Duopharma Marketing Sdn Bhd
11	Johnson & Johnson Sdn Bhd
12	Dr Reddy's Laboratorires Sdn Bhd
13	Transmedic Healthcare Sdn Bhd



Astellas Pharma (M) Sdn Bhd

Pavilion Damansara Heights, Unit 9.02 and 9.03, Level 9, Corporate Tower 2,
3, Jalan Damanlela, Pusat Bandar Damansara, 50490 Kuala Lumpur.
Tel : +603-2022 6999
Fax : +603-2022 6988/977
Website : www.astellas.com

Astellas Pharma is a global pharmaceutical company dedicated to improving the health and well-being of people worldwide. Headquartered in Japan, Astellas focuses on the discovery, development, and commercialization of innovative therapies in areas such as oncology, urology, immunology, and neurology. The company is driven by cutting-edge research and technology, striving to address unmet medical needs and provide patients with life-changing treatments. With a commitment to sustainability and ethical business practices, Astellas is a leader in advancing healthcare solutions across the globe.



AstraZeneca Sdn Bhd

The Bousteador Tower, Level 12, No. 10, Jalan PJU 7/6, Mutiara Damansara,
47800, Petaling Jaya, Selangor, Malaysia.
Tel : +603-7624 3888
Fax : +603-7624 3999

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

In Malaysia, we are currently one of the top pharmaceutical companies and we are committed to continued innovation, close customer relationships, people development and an ethical responsible approach to business, with an aim to make a difference to the lives of patients and the healthcare professionals.

Our Malaysia marketing company- AstraZeneca Malaysia Sdn Bhd, was established in 1981 and in 2019, the company announced a commitment to invest more than RM500 million (USD125m) in Malaysia over the next five years demonstrating a strengthening commitment towards patients, innovation and talent development in the country and rolling out new robotic and cognitive technology designed to improve efficiency and drive productivity across the Company's global operations.

In addition, a new Global Business Services hub will be equipped with cutting-edge robotic technology and automation to support financial, accounting and business services for AstraZeneca operations in the Asia Pacific region. The Robotic and Cognitive Centre will deliver 'digital disruption' in day-to-day operations, bringing greater efficiency and improving productivity that will be scaled across global operations using Robotic Process Automation, mimicking human actions by performing repetitive rules-based tasks across multiple applications.

AstraZeneca Malaysia marketing company's vision is to push the boundaries of science to deliver life-changing medicines that addresses unmet medical needs in non-communicable diseases such as Cardiovascular, Diabetes, Renal Diseases and Cancer as well as Respiratory Illnesses.

We are aiming to treat, prevent, modify and in the future, even cure. It is only by enhancing our understanding of disease biology and uncovering new ways of targeting the drivers of disease that we will create the next generation of therapeutics across our main therapy areas.

Beyond accelerating our innovative pipeline to patients, AstraZeneca Malaysia partners with local stakeholders in Malaysia to increase healthcare access, stimulate innovation and improve outcomes through 'beyond the pill' approaches.



Bristol-Myers Squibb (Singapore) Pte Ltd

80, Marine Parade Road, #20-01 / 09 Parkway Parade, 449269, Singapore.
Tel : +65-6345 0822

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.


Dr. Reddy's Laboratories Malaysia Sdn Bhd

Unit No. SO-29-07 and SO-29-08, Menara 1, Strata Office, No. 3, Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Malaysia.

We started in 1984 with a modest investment and a bold vision. We were the first Asian pharma company outside Japan to list on the New York Stock Exchange in 2001. We are committed to the highest standards of compliance, ethics and quality in every activity that we undertake.

Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients' needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically differentiated assets and digital healthcare.

For four decades, Dr. Reddy's Laboratories has stood for advancing healthcare through access, affordability and innovation. Our work has been guided by our core tenets of deep science, progressive people practices and robust governance. 'Good Health Can't Wait' has become a movement and call to action for all of us, and good health encompasses people, planet and patients.

Today, with research and development centres, manufacturing facilities and commercial presence across the globe, we serve over half a billion patients worldwide. We are grateful for the trust our patients and stakeholders have had in us throughout our journey. We will continue to work on strengthening our core further and building the future of healthcare as we aim to touch the lives of over 1.5 billion patients by 2030.


Duopharma Marketing Sdn Bhd 197601001745 (27754-W)

Lot No. 2, 4, 6, 8 & 10, Jalan P/7, Seksyen 13, Kawasan Perusahaan Bandar Baru Bangi,
43650 Bandar Baru Bangi, Selangor Darul Ehsan, Malaysia.
Tel : +603-8924 2188
Fax : +603-8925 7930
Website: www.duopharmabiotech.com

As a Malaysian pharmaceutical company, Duopharma Biotech Berhad believes in creating equity in healthcare for all Malaysians – empowering people to live a better life via accessible and affordable healthcare. Through our professional expertise and resources, we aim to offer every person access to medicines, health supplements and healthcare tools- all proudly made in Malaysia.


Ipsen Pharma Singapore Pte. Ltd

#10-03, 20 Anson Road,
Twenty Anson, 079912, Singapore.
Tel: +65-6850 0700

Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centres around the world.


Johnson & Johnson Sdn Bhd (Co. No 3718-D)

Level 8 the Pinnacle, Persiaran Lagoon Bandar Sunway
46150 Petaling Jaya Selangor Darul Ehsan, Malaysia
Tel: +603-7661 4500

Johnson & Johnson is committed to redefining healthcare: connecting the best of Health & Care for every provider for every patient, for everyone.

Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow. Therapeutic areas include Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. Specifically for Oncology, one of our commitments is to improve patients diagnosed with genitourinary cancers


Merck Pte Ltd

2 Science Park Drive, #05-01/12 Ascent Building, Singapore 118222
Mobile : +65-9295 4388
Fax : +65-6890 6778
Email : www.merckgroup.com

Merck is a vibrant science and technology company, and we believe in science as a force for good. We uniquely combine three specialized, innovation-driven businesses: Life Science, Healthcare, and Electronics.

Sparkling Discovery, Elevating Humanity as our unifying vision

- In **Life Science**, we help deliver novel therapies to treat chronic disease and provide other solutions for a safer, more sustainable world.
- In **Healthcare**, we help to create, improve and prolong lives worldwide with pioneering therapies that address unmet medical needs.
- In **Electronics**, we provide the material related solutions needed for our customers innovation to power the digital world of tomorrow.

Together as one team Merck, we are dedicated to Sparking Discovery, Elevating Humanity for a brighter, more sustainable future! This is our promise to millions of customers, patients, and communities worldwide.


Merck Sharp & Dohme (Malaysia) Sdn Bhd

B-22-1 & B-22-2, The Ascent Paradigm, No 1, Jalan SS7/26A, Kelana Jaya,
47301 Petaling Jaya, Selangor, Malaysia
Tel: +603-7499 1600
Website: www.msd.com

Merck Sharp & Dohme (MSD) Malaysia is a leading research-intensive biopharmaceutical company committed to saving and improving lives. As a subsidiary of Merck & Co., Inc., with headquarters at Rahway, NJ USA, Merck is known as MSD outside of the US and Canada. The company specializes in discovering, developing, manufacturing, and marketing innovative healthcare products to address critical health challenges and enhance patient outcomes.


Novartis Corporation (Malaysia) Sdn Bhd

Level 18, Imazium, No. 8, Jalan SS 21/37, Damansara Uptown, 47400 Petaling Jaya, Selangor Darul Ehsan.

Novartis has a long heritage and legacy in Malaysia. Established in 1971, we are a leading multinational company employing close to 700 associates who work in the Novartis International division and Novartis Corporate Center, Kuala Lumpur. Through our over 50-year presence in Malaysia, Novartis Malaysia continues to deliver on its corporate purpose of reimagining medicine to improve and extend the lives of over 32 million Malaysians.

In 2022, Novartis Malaysia was recognized as Sponsor of the Year by Clinical Research Malaysia for initiating 24 new clinical trials. We also have a proven track record of expanding access to our innovative medicines in private or public via collaborations with the Ministry of Health. Through these collaborations, Novartis has succeeded in touching the lives of more than 1.7 million Malaysian patients.

Novartis Malaysia's office is located in the new cutting-edge building called Plaza Imazium in Damansara Utama, Petaling Jaya. Novartis Malaysia occupies 2 floors and was one of 20 offices in Malaysia to be LEED Gold certified and the first office to be WELL Silver certified



Novugen Pharma Sdn Bhd

3, Jalan Jururancang U1/21, Hicom-Glenmarie Industrial Park,
40150 Shah Alam, Selangor

Novugen is a wholly owned subsidiary company of a UAE based group, SciTech International. With over 30 years of experience in the healthcare industry, the company is equipped with vast and successful experience of venturing into strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's passion for science, bold global strategy and wealth of international experience prepared us to respond to complex challenges of bringing hard-to-source and technology-intensive pharmaceutical products to the market.

Novugen specializes in niche and difficult to formulate generics for all therapeutic areas of general and oncology medicines while meeting stringent global quality standards. With vertically integration from Active Pharmaceutical Ingredients (API) to Finished Products R&D and manufacturing based in Malaysia, it gives us greater control over the supply chain. Malaysia is also home to our state-of-the-art manufacturing facilities, designed by globally renowned European pharmaceutical engineering firm following stringent regulatory requirements by authorities across the globe including USFDA, EMA, PIC/S and WHO.

We are the first USFDA approved pharmaceutical company in Malaysia and the Only in Southeast Asia with manufacturing facilities focusing on oral solid dosage forms for general medicines and highly potent Oncology drugs. The accreditation by the U.S. federal agency positions us as the first pharmaceutical company in the country to manufacture high-quality medicines locally in Malaysia for the U.S. market. As part of our Middle East export strategy, our manufacturing facilities are also Halal compliant, a reflection of our commitment to respond to the increasing demand for Halal products in the international and local market.

Novugen enhances in achieving the desired quality of our products with systematic Quality by Design (QbD) approach. With our robust team of professionals and scientists, advanced R&D centre and USFDA Approved manufacturing facilities in Malaysia, we are committed to ensure early access of high-quality products that lack robust generic alternatives due to their complexity. We strive to strengthen the accessibility of affordable and global quality standard products in Malaysia with same efficacy to medicines exported to the U.S.

Novugen's business outlook targets a wider market penetration globally. Our focus is on ASEAN, CIS, GCC, Africa & LATAM regions and expanding through distributor channels in the U.S., Europe and Canada markets. Today, Novugen is present globally with 5 offices worldwide, including, Malaysia, the U.S., Uzbekistan, UAE, and Pakistan. In 2030, we are targeting to enter the global market of 89 countries worldwide, covering all continents.

The people behind Novugen are united to achieve one common vision to be the largest and fastest growing pharmaceutical company in Southeast Asia by 2025, competing in global markets. Our aim is to make an impact on Malaysia's economy, being a self-sufficient nation, capable to supply quality medications locally and increasing the country's power to export. Devoted to the cause, we hold the highest standards of ourselves, finding ways to serve patients locally and all over the world with life-changing medicines.



SYS Healthcare Sdn Bhd (1217995-H)

No. 1-1 (1st Floor), Jalan Damai Raya 6,
Alam Damai, 56000 Kuala Lumpur,
Wilayah Persekutuan Kuala Lumpur
Tel : +603-9108 4888
Fax : +603-9102 4848

SYS Healthcare is a home-grown medical device distributor specialising in the fields of Urology, Gastroenterology, Otorhinolaryngology (ENT), General Surgery, O&G, Respiratory and CSSD. We strive for excellence and pride ourselves in continuously supporting Hospital services.



transmedic
advancing medical technologies

Transmedic Healthcare Sdn Bhd

B4-1-1, Solaris Dutamas, No 1, Jalan Dutamas 1,
50480 Kuala Lumpur, Malaysia
Tel : +603-6205 3888
Fax : +603-6205 4062
Website : www.transmedicgroup.com

Headquartered in Singapore, we are a leading independent distributor of innovative medical technologies, specializing in therapeutic areas such as Cardiovascular, Orthopaedics, In-vitro Diagnostics, Ophthalmology, Blood Therapy, Radiation Oncology, Endovascular, and Abdo-Pelvic.

With over 40 years of local expertise, we provide healthcare professionals and institutions throughout ASEAN and Hong Kong with globally sourced solutions, trusted networks, and dedicated support to enhance patient care.

Transmedic's regional presence spans Singapore, Malaysia, Thailand, Indonesia, Hong Kong, the Philippines, and Vietnam, empowering healthcare systems for better outcomes.



Conference Secretariat

SURF 2025

Conference Secretariat

Malaysian Urological Association

Unit 6-5, Bangunan Perdagangan D6,
801 Jalan Sentul, 51000 Kuala Lumpur, Malaysia.
Email : malaysianurologicalassociation@gmail.com
Website : www.mua.my

Conference Venue

Zenith Hotel Putrajaya
Jalan P2a, Presint 2, 62000 Putrajaya,
Wilayah Persekutuan Putrajaya

Registration Fees Category

Category	Before 22.05.2025	After 22.05.2025
Full Delegate registration	RM 550	RM 700
Medical Officer, Scientists and Non clinician	RM 400	RM 500
International Delegates	USD 200	USD 200

* The above rate inclusive the GST 8%. The Malaysian government officially implemented the Goods & Services Tax (GST) on 1 April 2015. Hence effective from this date, a 8% GST will be included into the registration fees. You may obtain further information on GST from the Royal Malaysian Customs Department website at www.gst.customs.gov.my.

Registration Form

Please return the completed Form to the Secretariat with appropriate fees as early as possible to ensure receipt of the Conference bag and the complete set of conference materials upon checking in at the Conference Registration Desk. Photocopies of the form may be used.

Payment Details

Name of the Account : Malaysian Urological Association
Account Number : 514075606138
Bank Address : Malayan Banking Berhad, Lot AG 1-2 &
AG 9-10, Block A, Plaza Pekeliling,
No. 2, Jalan Tun Razak, 50500
Kuala Lumpur

Entitlements

Full registrants will be entitled to:

- Admission to all lectures and symposiums
- Conference bags and materials
- Name badge and Conference bag
- Admission to the exhibition areas
- Coffee/Tea
- Lunches

Scientific Sessions

Plenary session

Date : 21st June 2025
Venue : Grand Ballroom, Level 1, Zenith Hotel Putrajaya
Time : 0800 – 2030

Date : 22nd June 2025
Venue : Grand Ballroom, Level 1, Zenith Hotel Putrajaya
Time : 0800 – 2030

Insurance and Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private properties of participants during the conference. Participants should make own arrangements with respect to personal insurance

Conference Website

Regularly updated information on registration, hotel reservation and scientific programme are available online at www.mua.my

Conference Language

The Official language of the Conference will be English.

Certificate of Attendance

A certificate of attendance will be issued to all delegates.

Letter of Invitation

Upon request, the Organising Committee will issue a letter of invitation. The sole purpose of the letter is to facilitate the delegate's travel and visa arrangements. The invitation does not imply provision of financial support. Letters of invitation may be requested by individuals from the Conference Secretariat by email : malaysianurologicalassociation@gmail.com.

Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private properties of participants during the conference. Participants should make own arrangements with respect to personal insurance.

DISCLAIMER

Whilst every attempt will be made to ensure that all aspects of the Conference published in this announcement will take place as scheduled, the Organising Committee assumes no responsibility should any of these fail to materialize for any reason.

ACKNOWLEDGEMENTS

SURF25 | Putrajaya,
Malaysia
21 - 22 June 2025
Section of URo-Oncology Forum

The Organising Committee of the Section of Uro-Oncology Forum 2025
expresses its grateful thanks to the following
for their contribution and support for the Conference.

Astellas Pharma (M) Sdn Bhd

AstraZeneca Sdn Bhd

Bristol-Myers Squibb (Singapore) Pte Ltd

Dr. Reddy's Laboratories Malaysia Sdn Bhd

Duopharma Marketing Sdn Bhd

Ipsen Pharma Singapore Pte Ltd

Johnson & Johnson Sdn Bhd

Merck Pte Ltd

Merck, Sharpe & Dohme (M) Sdn Bhd

Novartis Corporation Sdn Bhd

Novugen Sdn Bhd

SYS Healthcare Sdn Bhd

Transmedic Healthcare Sdn Bhd



UPM
UNIVERSITI PUTRA MALAYSIA



Malaysian
Oncological
Society



MALAYSIAN
UROLOGICAL
ASSOCIATION

